I would wonder how that second tranche of 100K that he put in is doing, or was he BSing? More pain I fear as the company is going into 89 or more countries for their adult indication, they are studying and re-studying the adult possible numbers, they are studying potenatial market for pediatric patients. The peds patients will give you a much lower return. First off, you will have to really have a much longer test study for them than the flimsy clincal that they had for adults. You also will much bigger dangers putting children on a med like this for life. So at the same time you are trying to do all of this by yourself you're going to have shareholders demanding to see profits. On top of that in 2015 the actual med itself goes off patent so what you have left is the dosing schedule as your patent......I don't think this will hold. This stock could do an AMRN, we'll see. t
It's really more like DB, and others are trying to get their clients out in an orderly fashion. t
8) He sounded very subdued IMO, he noted that they were not going to give out numbers any more, just revenues, and that they may not give out Q4 numbers or estimates......due to ?seasonal factors? The fourth quarter is always the hardest to get numbers for according to him. He stated that the company didn't understand seasonal factors and it may relate to someone wanting to wait until after the holidays before embarking on the diet and meds.
9)I get the impression he is trying to buy time and that things aren't going as well for them as people think. He is hoping for data on peds patients so he can tell investors that they have X amount of potentially more patients to be able to get on the drug. He really hemmed and hawed when the moderator ask for Q4 data and if it would show continued growth along the same growth curve as previously. From an expense stand point they have one sixth of their company employee-wise being used for the COMPASS program to get insurance coverage for their patients. They are supposed to be expanding into all of these countries. They are doing pediatric studies trying to find out how many patients they can potentially get to the potty, they are restudying the ?adult populations? And they intend to start clinical trials in peds patients in 2014. That is all fine and good, but when you are already losing money...how many new patients will you have to bring on scale-wise to get earnings with all of those goals and you already are not making money. The first rule in business is follow the money. The first sign of someone not telling the truth IMO is poor eye contact, second sign is constantly clearing your throat....Mr. Beer cleared his throat about 15 times in 34 minutes at points in the conversation where he had to get his gumption up. And just wait until you try and get an eight year old on a pill that makes you go like that. t
4)He also noted, like what I had thought of at first, but MF seemed to go the opposite on and that was approaching of the sales to different physicians. Mr. Beer noted that maybe AEGR should have hit cardiologists first rather than lipidologists. He noted that they were trying to catch up. He further noted that lipidologists see about 10 patients a week, and cardiologists about 35 patients a day. He explained that what they discovered was that cardiologists usually managed their own patients lipid-wise unless or until those patients had to go on apheresis and then they would turn them over to lipidologists. With about a ratio of 50:1 cardiologists to lipidologists that is huge potential number out there uncommitted. And he admitted that they felt some frustration in regards to not being able to get to as many cardiologists as they had wanted to.
5)He noted that they have what they call a COMPASS program. This division/program only tries to get patients covered for their meds. They originally had four, then eight, they expect to have 20 by year end and 40 by next year's end. When the moderator ask if that could be meant to show the rapid growth of the company as far as patient expansion he noted no, that he wanted to show the expense side of the business.
6)He noted that when he talked to other orphan biotech companies the thing that they all told him was that they expanded too late and they if they had the chance to do it over again they would have expanded earlier and so that is what AEGR is in the process of doing.
7)He mentioned all of the places that they were expanding to including Japan, Mexico, Brazil. They are getting up their sales force in all of these countries and they are doing "direct market research" in all of these countries. He noted over 89 countries.....that's about on rep for each country isn't it?
Thanks for calling me an idiot. Will try and repay you:
Listened to the AEGR CC. I think they are going to be back peddling:
1)After a nice introduction and the moderator was going to ask a second question Mr. Beer himself brings up the pediatric indication goal. He notes that they are now in the process of trying to see how many potential pediatric patients there are out there. He noted that they don't talk about it because juxta is only indicated for adults.....then why bring it up without a question from the moderator? According to him AEGR is in the process of studying the pediatric potential and he noted that they were re-doing another adult study to check for ?further potential?. Another study in the adults looking to pick up patients with another study that they are paying for from an outsider agency?
2)Prior to that he noted that if the company felt ?comfortable? at the JPM conference they would talk about 2014 guidance. But he had to wait and see. He was very cryptic.
3)He noted that originally AEGR had hired 25 sales reps for the US and shortly thereafter hired another 12. He wouldn't divulge the amount of pharm reps they have now in the US because, "we are in a competitive environment in the US."
You can't keep people straight because you are nou too sharp. You also can't stay on task. If anyone looks at what I said they will see the truth. I didn't try and call you a Obama lover, and then later call you a KKK. Keep laughing till they can get the straight jacket on you. Still a tough nut to crack beyond 69. Still over priced, but you'll find out. t
You are really stupid, I've never said one word about insiders selling. When you get frustrated you resort to these tantrums. I did say about a week ago that 69 looked like a tough nut to crack. I have not said anything about Obama, or the KKK, or anything else in the middle. Tried to help you, enjoy your ride. t
To answer your question.....you must be mentally challenged and can't tell the difference or you are in denial that there is more than one person who thinks this is a poor investment.. t
Truth really is you want to bring attention to me and away from the ral issues. An old game, used by Hector Chavex...blame the Americans and keep the focus away from the real problems. t
The other individual pointed out some excellent facts as well. You don't want to let go of your easy street dream of 1400 to 6500 per share in value with a company that has a wounded CEO who has exhibited poor judgment in the past, that has one drug in the pipeline, that is trying to create an unnatural situation for the first time in history with trying to get a patent on a small molecule invented over 20 years ago using a flimsy numbers dose titration patent in the world of the internet where things are worldwide and people are attempting to get a much newer, more complex medicine....a biological declared a generic in India and you deny the fact that could happen with juxta?! You then declare your school yard laws that if that happens the rest of the world won't deal with the second most populous country in the world because they aren't willing to honor the flimsy patent that unnaturally tries to make countries pay just 20% less than the 350K that AEGR is trying to soak out of the US now for a drug that cost Dr. Radar 169K???!!! t
Man YG, make up your mind...am I going back to President Obama or am I a KKK? Kind of opposites don't you think, or maybe you don't. You have a lot of politics on your mind. That is why I want to help you see through that. All that Animal House prejudice in regards to my personal business doesn't change facts. Not telling you what to do with your money at all. Just presenting the other side in regards to what can/will happen while you are waiting for Obama or the KKK take over your world. t
Nice make up of numbers YG. You should have doubled em though for a more dramatic effect. You have a nice Thanksgiving. t
if you listen to that CC you find out that the patent for juxta in regards to material content is really only until 2015. That means that the "real" patent that holds everything together for AEGR is the number titration patent. I find it extremely difficult to believe that when Americans are protesting over in India right at this time and trying to have India disallow a patent to not be valid for a biological for an antiviral product for HepC made by GILD that both Americans, and other countries, particularly Brazil, India, and China are going to pay $400K per patient per year when all they have to do is make one strength of the drug, say 11mg and use that and titrate up and down from there. And just get it in this day and age from one locale...say India over the internet. When you listen to that CC MF the speaker noted that in Europe, and ROW they are going to try and make sure that their drug is not discounted 20% below what juxta is going for in the US. This to hold their pricing power in the US. If Arabs from truly harshly ruled countries can unite and conquer powerful regimes and it is because of the info derived over the internet I think it is fair to consider that juxta "regime" could fall prey to aggressive overseas pricing made known over the internet. Just locally the example comes through clear on a much smaller scale. If you write a prescription for Fenofibrate 165mg you will pay a pretty stiff price at the pharmacy. If you write for Fenofibrate 164mg the price for that generic is considerably less. Thus if this holds true I don't believe that Mipo will be able to hold the line in regards to pricing power either as a result of this juxta slippage that could very well take place. I could be wrong....but think about different countries, you have to know that they can do as they please. If the material content patent only lasts until 2015 how can the US fault them for going around the number patent game...and it is a game
Mylan Labs announces its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India (43.24 +0.57)
Co announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name Hertraz.
Was sent here to save your equity. Looks like 69 is a barrier. Happy Thanksgiving. t
NO is the short answer. The inability to generate enough money to expand indications will affect the share price. t
You are playing a trick to get away from the real issues. I don't know if you are threatening me but if you are let me know in private and we'll meet. My info could have been used as a tool re-evaluate your position. Instead you play ego games and look for an edge in a side-argument that doesn't relate to what I've said or pointed out. Think about it. Do I control the money for AEGR, do I make the decisions? Am I going to go on Cramer? Do I have access to your money at least indirectly? And, when you have dealt with me you haven't been exactly mr. polite yourself. So IMO I owe you nothing, you owe me nothing. This board is for opinions. I gave you opinions and I gave you information in a context to view. Does staying at the Waldorf Astoria seem like logical business decision to come from a CEO of a paltry company, or does it seem like a Dennis Kozlowski(sp) thing? Drop the idea that you are arguing with me and you want to win the argument. Does that raising the price due to demand really make sense for a disease that at the time they were only treating less than 300 people for. It won't be me that screws you out of your money, and my long, short, hedged position will do nothing to help or hinder your monetary status. And believe me if you want to me in person I won't be mister pansy ranger going to turn you into the SEC. t